Beginner's Mind

The world has grown quiet about climate change. Too quiet. We scroll past floods, fires, droughts… and move on with our day. As if the problem solved itself. As if we’ve earned the luxury to look away. Janos Pasztor has spent 40 years inside the rooms where climate decisions are made — from serving as UN Assistant Secretary-General for Climate Change to advising presidents, prime ministers, and global institutions. And in this SPARK20 highlight episode, one truth stood out: We are not done with climate change. We are only entering its most consequential chapter. This is not a doom story. It is the story of a man who still believes humanity can choose a better future — if we’re willing to face the questions we’ve been avoiding. What You’ll Learn in 20 Minutes Why global warming accelerates even as we reduce emissions (00:01:15) And why governments are still “not addressing the issue sufficiently.” Why adaptation alone cannot save us (00:01:54) And what the real limits of adaptation look like. Why Janos believes we may need to cool parts of the planet (00:02:32) And why no political leader wants to say it out loud. How climate diplomacy changed since the 1980s — and why it matters now (00:03:32) Including the rise of China in global negotiations. Why capitalism itself may need to evolve (00:08:05) And what this means for investors, innovation, and global stability. What geoengineering really is (and is not) (00:09:16) Forget the internet myths — this is the factual explanation. Why volcanic eruptions hold a clue to future climate solutions (00:12:04) Why SRM is scientifically feasible — and politically dangerous (00:17:11) The technology is simple. The governance is not. Why the biggest risk of SRM is not cost — but consent (00:17:44) And what happens when societies don’t get a say. What a unilateral climate intervention could trigger (00:20:33) A scenario every policymaker should hear. Why Janos still believes in a brighter future (00:21:07) A rare moment of optimism from someone who has seen every side of the crisis. Quotes to Carry With You 📌 “Global temperatures continue to rise — and the world is not ready.” (00:01:15) 📌 “We must consider whether the time has come to start cooling parts of the planet.” (00:02:32) 📌 “Three degrees of warming is cuckoo land. You simply cannot adapt to that.” (00:18:23) 📌 “Technology is not the issue. It’s cheap. The real question is: do societies want this?” (00:17:11) 📌 “I wouldn’t be here if I didn’t believe we can still get this right.” (00:21:07) Why This Conversation Matters Because climate change isn’t a chapter we finished. It’s the foundation on which every other chapter of the future will be written — our economies, our food systems, our borders, our investments, and the lives of our children. And while Elon Musk may one day take humans to Mars, no one alive today will move there. This planet is the one we must keep habitable. Janos Pasztor is a reminder that realism and hope are not opposites — they’re partners. 👉 Listen now. Share it forward. Keep the conversation alive. Send us a text Support the show Join the Podcast Newsletter: Link

Europe leads the world in discovery — yet too often, its breakthroughs never become global companies. Billions in research funding turn into patents, not products. While others build empires from ideas, Europe risks becoming the world’s laboratory — brilliant, but broke. That’s the paradox at the heart of this conversation. In this episode, Karl Nehammer, Vice-President of the European Investment Bank (EIB) and former Chancellor of Austria, joins Christian Soschner live at BIO-Europe 2025 to discuss how Europe can turn its world-class science into world-class companies. He shares how leadership forged in crisis can rebuild confidence, competitiveness, and growth — and why every crisis hides an opportunity to start thinking differently. 💡 What You’ll Learn in This Episode 1️⃣ Why Europe’s innovation system struggles to turn discovery into scale 2️⃣ How the EIB can bridge the gap between science, capital, and market impact 3️⃣ Lessons from leading through COVID-19, the energy crisis, and diplomatic challenges 4️⃣ Why changing culture and regulation is key to Europe’s competitiveness 5️⃣ The mindset Europe needs to move from surviving to building 💬 Quotes from Karl Nehammer 🧭 Timestamps (00:00:00) Opening – Why Europe Struggles to Scale (00:03:33) Karl Nehammer – Leadership Lessons from Crisis (00:06:21) Europe’s Innovation Challenge – Science vs. Commercialization (00:09:17) Life-Science Resilience – Lessons from COVID-19 (00:12:52) A Realistic Vision for Europe’s Future (00:17:05) Inside the European Investment Bank – Building Bridges Between Capital and Innovation (00:18:59) Empowering Founders – Karl Nehammer’s Message to Europe’s Builders (00:20:14) Closing – Optimism, Collaboration, and Confidence 🎙️ Beginner’s Mind Top 10% globally. The leading podcast for founders, investors, and policymakers shaping the future of biotech, deep tech, and innovation. Follow the show to explore more conversations like this one — where science meets strategy and leadership builds the future. Send us a text Support the show Join the Podcast Newsletter: Link

Most founders dream of raising millions. Few survive the 153 “no’s” it takes to get there. Behind every biotech breakthrough lies exhaustion — late-night calls, failed rounds, and investors who walk away at the finish line. What separates the ones who make it isn’t luck or timing — it’s resilience built into process. In this episode, Jason Foster, CEO of Ori Biotech, shares how he transformed relentless rejection into a billion-dollar trajectory. From rebuilding cell-therapy manufacturing to leading global teams through economic storms, Jason reveals how founders can systematize grit, master storytelling, and survive when everything seems to fall apart. You’ll learn how to navigate fundraising winters, why leadership begins with self-care, and how to build companies that endure long after the hype fades. If you’ve ever doubted your path as a builder, this conversation will remind you that resilience is not a trait — it’s a practice. 💡 What You’ll Learn in This Episode 1️⃣ The real reason most founders fail long before capital runs out 2️⃣ How to turn rejection into momentum using process and habit 3️⃣ Why storytelling is the most underrated skill in biotech leadership 4️⃣ How resilience and self-care directly drive performance and valuation 5️⃣ The mindset that separates enduring companies from short-term success 👤 About Jason Foster Jason Foster is the CEO of Ori Biotech, a leading innovator transforming cell and gene therapy manufacturing. With 20+ years in global health, he has raised over $140M, led companies through IPO-level growth, and serves as a mentor and investor to emerging founders in life sciences. His mission: make advanced therapies accessible to every patient, everywhere. 💬 Quotes That Might Change How You Think (00:14:09) “There are cures for cancer today, but patients can’t reach them — access must change.” (00:37:22) “The science is extraordinary — but if we can’t make it at scale, it means nothing.” (01:22:17) “Purpose, not money, drives talent to transform lives through innovation.” (01:46:17) “Fundraising is a war of attrition — constant rejection tests your resilience more than your idea.” (02:02:16) “You only have to get up one more time than you’re knocked down.” 🧭 Timestamps to Explore (00:02:00) Embracing Hard Challenges — How Biotech Founders Build Resilience That Lasts (00:13:40) The Unacceptable Truth: Cures Exist, Yet Patients Still Can’t Access Them (00:26:23) Navigating Cultures — What European and American Biotech Leaders Can Learn From Each Other (00:32:52) Why Great Science Isn’t Enough Without Commercial Viability (00:39:19) Revolutionizing Cell Therapy Manufacturing — The Seven-Day Bottleneck Explained (00:50:11) Automation and Digitization — Unlocking Scalable Patient Access in Cell and Gene Therapy (01:09:30) Rethinking Capacity Utilization — Making Regional Biotech Manufacturing Centers Work (01:14:27) Mass Personalization — The Future Delivery Model for Advanced Therapies (01:23:00) Purpose-Driven Talent — The Secret to Retaining Top Biotech Performers (01:32:18) Fundraisin Send us a text Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Imagine waking up to find your company’s most valuable IP leaked—not by hackers, but by the very AI tools you trusted. This isn’t a distant scenario; it’s happening inside pharma and biotech right now. And the cost isn’t just financial—it’s patient lives, broken trust, and an industry on the edge of losing credibility. In this episode, Kat Kozyrytska shares how leaders can act before invisible risks become catastrophic. From her personal journey in post-Soviet Ukraine to building frameworks in global biotech, Kat reveals why “yesterday problems” with AI demand urgent attention today. You’ll learn how data privacy failures propagate quietly, why embedding organizational values into AI is essential, and how collaboration across companies can safeguard innovation and accelerate therapies. The future of biotech won’t be secured by hype or speed—but by trust, ethics, and the courage to act before it’s too late. 🎧 What You’ll Learn in This Episode 1️⃣ Why “yesterday problems” with AI in pharma are already costing billions 2️⃣ How data privacy failures silently erode trust, IP, and patient safety 3️⃣ The difference between collaboration and competition in biotech innovation 4️⃣ Why embedding organizational values into AI is no longer optional 5️⃣ The future of drug discovery, clinical trials, and manufacturing in an AI-first world 👤 About Kat Kozyrytska Kat Kozyrytska is the Founder of the Cell Therapy Manufacturability Program and a global thought leader at the intersection of biotech and AI. With roots in Ukraine and a career spanning MIT, Stanford, Thermo Fisher, Sartorius, and global biotech startups, she bridges technical depth with ethical foresight. 💬 Quotes That Might Change How You Think (00:14:50) "AI can amplify good or bad behaviors — the choice is ours." (00:38:14) "Discovering dark personalities is like learning Santa isn’t real — traumatic, but suddenly everything makes sense." (01:03:26) "AI speaks with absolute confidence, but confidence is not the same as truth." (01:20:22) "AI gives us a rare chance to embed ethics and values into innovation." (01:57:01) "If personalized therapies work better, we have an ethical duty to deliver them." 🧭 Timestamps to Explore (00:05:16) From Math to Medicine – Kat’s unexpected path from equations to biotech leadership (00:09:38) Inside a Nobel Lab – How neuroscience breakthroughs shaped her ethical lens (00:12:27) Shadow AI – Why biotech leaders can’t wait to govern hidden systems (00:23:03) Data Sharing Paradox – Collaboration vs confidentiality in pharma innovation (00:31:31) Neurobiology of Manipulation – How dark personalities exploit human trust (00:41:18) Hidden Privacy Risks – What your everyday data footprint really reveals (00:52:17) Soviet Control vs American Individualism – Lessons for AI governance today (00:57:30) The Danger of One Answer – Why converging on a single AI truth is risky (01:02:51) Confidence ≠ Expertise – Rethinking how we trust AI in science (01:18:16) Embedding Core Values – How leaders can align AI with human ethics (01:51:28) Breaking Down Silos – Th Send us a text Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Most founders obsess over products. Jensen Huang built a $3 trillion company by obsessing over inevitabilities. This episode unpacks The NVIDIA Way by Tae Kim—the definitive account of how NVIDIA went from near-death startup to the world’s most valuable chipmaker. More than a history, it’s a manual for founders and VCs navigating the messy, high-stakes stretch between Series A and IPO. But this isn’t just about NVIDIA. It’s about you—if you’re scaling in deep tech, where survival depends less on genius inventions and more on how you engineer resilience, culture, and urgency into your system. I walk you through 7 scaling lessons that matter now—from why pain is a founder’s greatest teacher to how vision and culture become moats no competitor can copy. Each principle is grounded in NVIDIA’s story, translated into today’s market reality, and wrapped with coaching prompts you can act on this week. Key Takeaways: Timestamps: (00:00) Why This Episode Matters (02:18) The Big Idea of The NVIDIA Way by Tae Kim (04:36) Who is Tae Kim? (08:15) Lesson #1: Pain and Suffering Are the Recipe for Greatness (12:35) Lesson #2: Your Reputation Is Your Currency (17:05) Lesson #3: The Innovator’s Dilemma Will Come for You (21:45) Lesson #4: Lead With Context, Not Control (25:18) Lesson #5: Don’t Just Sell the Product—Sell the Vision (30:00) Lesson #6: Culture Outruns Capital—and the Competition (34:32) Lesson #7: Build Urgency Into the System (38:30) Key Takeaways—3x Reading + 25 Years in Public Markets, VC, and Scaling Deep Tech (41:24) Reflection Why Listen: Found this valuable? Like, share, and follow. Every signal grows the show—and helps bring you more playbooks from the world’s most resilient companies. 🎙️ - Beginner's Mind. Top 10% global. #1 deep tech podcast. 200+ episodes. Send us a text Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

How do you succeed in a business where being wrong is the norm? Marc Penkala has lived both sides of the table: as an entrepreneur who built, sold, and failed with companies—and now as a venture capitalist running his own fund. What makes his story different is the radical honesty about what actually drives success in venture: failure, timing, and taking risks that look stupid at first. This Spark20 episode distills Marc’s hard-earned lessons into a 20-minute masterclass for founders, investors, and policymakers navigating uncertainty. What you’ll learn Timestamps & Quotes 📌 (00:00:38) Entrepreneur → VC “My route into venture capital felt like a paid executive MBA… I built, I sold, I bankrupted, and then I joined the so-called evil side to truly understand investors.” 📌 (00:03:31) Failure as Fuel “Failure is the bigger success… many of my failures turned into the best things that ever happened.” 📌 (00:05:32) Credibility Through Scars “If I had never built a company, how could I authentically tell a founder I can help them?” 📌 (00:07:29) Wrong = Right in Venture “As a VC, you’re more often wrong than right. And strangely, the more you’re wrong, the higher your actual output.” 📌 (00:10:38) When Tourists Arrive, Leave “The moment angels and LPs with no clue flood the market, you literally have to stop investing. That’s when the tourists arrive.” 📌 (00:12:22) Outliers Make the Portfolio “One angel had ten bets—two of them gorillas and Tier. Didn’t matter what else he had—the outliers alone defined him.” 📌 (00:13:02) Europe vs. US Mindset “US startups think in billions. European startups think in millions. That mentality shift is everything.” 📌 (00:15:02) Stupid Ideas Win “If everyone agrees it’s a great deal, don’t do it. The best investments sound like the stupidest idea at first.” 📌 (00:17:42) Why Down Markets Build Giants “In down markets, founders get humble, go back to fundamentals, and focus on capital efficiency. That’s why the best companies come from downturns.” Endnote This isn’t just a highlight reel—it’s a reminder that in venture capital and entrepreneurship, the rules are upside down. Being wrong isn’t a weakness—it’s proof you’re taking the swings that matter. 👉 Listen now, and share it with someone who needs to think bigger. 🎙️ With over 200 interviews, panels, and livestreams, Beginner’s Mind ranks in the Top 10% globally—and is recognized as the leading deep tech podcast for Send us a text Support the show Join the Podcast Newsletter: Link

Here’s the harsh truth: If your business model can’t survive a spreadsheet, it won’t survive the market. Every year, ambitious founders pour months into product, pitch, and brand—yet the single biggest reason startups die isn’t funding, it’s flawed modeling. What are the four variables investors use to spot winners before anyone else? In this episode, investor and hands-on builder Alex Oppenheimer (Founder & GP at Verissimo Ventures, ex-Facebook IPO, ex-NEA, Monday.com advisor) reveals why most startup advice misses the point—and how the best founders reverse-engineer success long before a single euro is raised. 🎧 Watch now to learn: 1️⃣ The business model simulation Alex uses to kill (or greenlight) a deal in under an hour 2️⃣ The one thing top VCs always ask founders—but almost nobody prepares for 3️⃣ Why a founder’s “calling” is more important than their credentials 4️⃣ How to avoid the European trap of ignoring leverage and failing to scale 5️⃣ The subtle mindset shift that separates bold investors from the herd—and how to apply it to your own company 👤 About Alex Oppenheimer Stanford-trained engineer, ex-Morgan Stanley tech banker, NEA Series A investor, Monday.com operator, and now founder of Verissimo Ventures—a fund that bets on weird tech and next-gen software models in Israel, the US, and Europe. 💬 Quotes That Might Change How You Think: (00:59:00) “If I don't build this, nobody else will—that’s the founder’s true calling.” (01:12:45) “How can you know what data to collect if you don’t know the model?” (01:22:36) “The real job of an investor is helping great founders not mess it up.” 🧭 Timestamps to Explore: (00:04:00) Quitting Corporate Venture—The Decision That Changed Everything (00:11:50) What Business Modeling Is (and Isn’t) (00:18:30) Trusting the Founder Over the Deck (00:24:40) Venture Capital and the Power of Naivete (00:34:03) Inside the Facebook IPO Data Room (00:44:38) Lessons from Betting on Outliers (00:49:48) Leaving NEA to Build Israel’s Next Scaleups (01:02:32) From Frustration to Founding a Venture Fund (01:10:57) Why Business Modeling Remains a Blind Spot (01:14:09) Redefining Value Investing in Venture Capital (01:15:50) Decoding Value with Core Variables (01:22:36) Helping Founders Avoid Unnecessary Pitfalls Early 🔔 Like what you hear? Follow the show and share this episode with one builder, founder, or investor you respect. Every share helps us bring new industry leaders and sharper insights straight to you. Subscribe now—your next breakthrough could be one episode away. 🎙️ Beginner’s Mind Top 10% globally. The leading podcast for VCs, operators, and anyone obsessed with building what comes next. Send us a text Support the show Join the Podcast Newsletter: Link

Why do Europe’s brightest founders still feel forced to leave for Silicon Valley—no matter how much money or talent we pour into the region? Every year, ambitious startups across Europe and CEE struggle to scale—not for lack of ideas, but because of invisible barriers that keep global success out of reach. Is it really just about capital—or is there a deeper mindset and playbook that only a handful of founders ever discover? In this episode, venture insider Enis Hulli (General Partner at e2vc, investor in 40+ startups, 3 unicorns, and builder of bridges from Istanbul to the Bay) pulls back the curtain on the real reasons US-based startups keep winning—and how founders from Turkey, Eastern Europe, and beyond can finally turn the tables. 🎧 Watch now to learn: 1️⃣ The “power law” that decides which founders build generational companies—and why most never see it coming 2️⃣ Why relationships, not pitch decks, determine who actually gets funded—and how to break through if you don’t have the right connections 3️⃣ How emotional resilience and founder mindset shape the fate of entire regions—not just individuals 4️⃣ The little-known risks of playing the European “safe game”—and how to engineer luck for outsized results 5️⃣ Tactical lessons on team building, brand, and why your anti-portfolio (the deals you missed) might matter even more than your winners 👤 About Enis Hulli Enis is General Partner at e2vc, a leading early-stage venture fund focused on scaling tech startups from Emerging Europe to global markets. With investments in 40+ companies (including three unicorns), he’s spent his career helping founders unlock the path from local player to world-class leader. 💬 Quotes That Might Shift Your Thinking: (01:30:44) “I don’t think we’ll see founders choosing Europe over the US in our…” (01:34:37) “There are twenty different ways to kill a reputation on any side of the…” (01:38:31) “To avoid complacency, I surround myself with people who make me feel like I…” 🧭 Timestamps to Explore: (00:16:58) How the Bay Area’s Talent Network Effect Became Unstoppable (00:20:48) Work-Life Balance vs. Blitzscaling—What It Really Takes to Go from Zero to One (00:25:43) Why Founders Trump Pitch Decks Every Time (00:30:38) The Perils of Planning for an Exit Too Soon (00:34:34) The Three Qualities Every VC Looks For—And Why Mindset Still Wins (00:40:30) How IPO Markets Shape (and Break) Venture Capital (00:43:52) Fundraising Mistakes That Kill FOMO and Crush Deals (01:12:58) Why Bay Area Mindset Still Outpaces Europe’s Best (01:30:44) The Real Reason Europe Loses Its Unicorns (01:34:37) Reputation, Relationships, and the Hidden Dangers of VC Control (01:38:31) How Top Investors Avoid Complacency and Stay Hungry 🔔 Follow the show and leave a review. Every follow, like, and share brings new global voices, industry leaders, and sharpest insights straight to you. 🎙️ Beginner’s Mind ranks in the Top 10% globally—and is recognized as the leading deep tech podcast for scientific entrepreneurship. Send us a text Support the show Join the Podcast Newsletter: Link

Still trying to optimize your health with guesswork and generic advice? Most people settle for “one-size-fits-all” supplements and hope for the best-missing out on the breakthroughs that only real data and personalization can offer. In a world flooded with empty promises, few realize how quickly tailored, science-backed solutions can transform energy, focus, and longevity. Enter Vadim Fedotov—ex-pro athlete, CEO, and co-founder of Bioniq, the health tech company bringing truly personalized care to the world’s top leaders, innovators, and athletes. In this eye-opening conversation, Vadim reveals why your biology is as unique as your fingerprint—and why the future belongs to those who personalize, measure, and adapt. Discover the systems, mindsets, and science behind optimizing human potential—without wasting time, money, or hope on outdated approaches. 🎧 Watch now to explore: 1️⃣ The fatal flaw in “one-size-fits-all” wellness—and how personalization is rewriting the rules 2️⃣ How AI, data, and regular feedback loops empower you to outpace your peers—at work, in health, and in life 3️⃣ Lessons from elite sports: why discipline, team dynamics, and feedback matter in business 4️⃣ The “feedback loop” secret that’s changing the supplement industry forever 5️⃣ Vadim’s vision for a future where your fridge, wearable, and AI coach work together to help you thrive 👤 About Vadim Fedotov Vadim is the co-founder and CEO of Bioniq, former CEO at Groupon, and a former professional basketball player with the German National Team and Buffalo Bulls. Driven by his passion for health optimization, he’s building a global, interdisciplinary network of thought leaders to put cutting-edge, personalized care within everyone’s reach. 💬 Quotes That Might Shift Your Thinking: (00:08:27) "Personalized health isn't a trend; it's the future of wellness." (00:15:54) "There is no single right diet, exercise, or routine—every body truly needs something different." (00:44:11) "Personalization in health is not a luxury anymore; it’s quickly becoming a necessity." (01:06:26) "You only fail when you give up—resilience defines success." (01:23:21) "Seventy percent of your health is determined by nutrition, not pharmaceuticals or medicine." 🧭 Timestamps to Explore: (00:03:32) Why Visionary Leaders and Families Move to Dubai (00:08:27) Personalizing Health Revolution How Data-Driven Wellness Changes Everything (00:09:27) Health as the New Wealth Post-Covid Insights (00:15:52) Busting Health Myths There’s No One-Size-Fits-All (00:18:28) Data Over Opinion Navigating Health Complexity (00:21:03) Olympic Research Sparks Personalized Health Innovation (00:23:51) When Obvious Solutions Don’t Exist—The Birth of Bioniq (00:25:40) When a "Dumb Idea" Becomes a Massive Opportunity (00:31:01) Setting Personal Health Goals With AI and Data (00:34:40) Real-World Feedback Loops Cut Through Wellness Hype (00:40:07) Data-Driven Breakthroughs That Save Lives (00:44:11) Why Health Personalization Is Now a Necessity (00:54:31) Leadership, Discipline, and Lessons from Elite Sports (01:01:04) Finding Pride and Resilience Against All Odds (01:23:21) Redesigning Healthcare Starting With Nutrition 🔔 Let’s Change the Future of Health—Together Follow the show. Leave a review. Share it with someone who’s ready to live—and lead—at their highest level. 🎧 Watch now and start your journey to real Send us a text Support the show Join the Podcast Newsletter: Link

How do you lead at the cutting edge of health, data, and AI—while staying deeply human? Angeli Möller has led global data science teams across pharma giants, co-founded one of Europe’s most ambitious AI alliances, and now builds high-performance biotech strategies with precision. But what truly sets her apart isn’t just her technical fluency—it’s her clarity, courage, and care in how she builds teams, solves problems, and pushes the boundaries of innovation. In this episode, Angeli opens up about the quiet frustrations that fuel her mission, the invisible cost of ignoring innovation, and the principles that guide her client work today. Whether you’re an investor, founder, or policymaker, her journey will reshape how you think about leadership, AI, and what truly moves the needle in healthcare. Here’s what you’ll take away: At the center of it all: a calm, fiercely smart leader who sees through the noise and builds what matters. As she says: “Start with the real problem. If you don’t understand the problem, AI won’t help you.” Timestamps & Topics 📌 (01:08) Missed AI Integration Costs – “It’s faster, more effective, cheaper—but it’s not part of the core business yet.” 📌 (03:57) AI vs. Real-World Drug Impact – “The question isn’t: does it use AI? It’s: does the medicine work?” 📌 (04:48) Post-Hype AI Fallout in Pharma – “Fraud led to disillusionment. And investors paid the price.” 📌 (06:39) Corporate Blind Spots in Innovation – “It’s a danger in business to think there’s nothing to learn from others.” 📌 (09:40) Building a European AI Alliance – “At first, pharma didn’t take us seriously. That changed with the data.” 📌 (11:02) Data Ethics and Regulatory Risk – “You can massively hurt your business through accidental bias.” 📌 (13:19) Data Access for Rare Diseases – “The only solution is to make that data safely available.” 📌 (15:22) Leadership Shift: From Bayer to Startup – “It felt too obvious. I needed something riskier, more meaningful.” 📌 (21:23) Three Core Leadership Traits – “Vision. Technical understanding. And knowing when to bring in others.” 📌 (22:27) Frictionless Health Tech Adoption – “It’s inevitable. The economics—and behavior nudges—are already shaping it.” This episode offers more than insight—it’s a playbook for building what’s next in health, tech, and leadership. 👉 Listen now, and share it with someone ready to shape the future. Send us a text Support the show Join the Podcast Newsletter: Link

Most founders add layers to gain control. Reed Hastings built an empire by removing them. This episode unpacks No Rules Rules—the leadership playbook behind Netflix’s rise from a DVD mail service to a global entertainment powerhouse. Co-authored by founder Reed Hastings and INSEAD professor Erin Meyer, the book reveals how to scale not through policy, but through trust, talent density, and extreme transparency. But this isn’t just about Netflix. It’s about you—if you’re building or investing in companies between Series A and IPO, where culture either compounds performance or quietly kills it. I walk you through 7 operational principles that deep-tech teams can apply now—lessons forged in crisis, growth, and reinvention. You’ll learn how to sunshine mistakes, pay like a pirate, and lead without becoming a bottleneck. Each principle is translated into coaching prompts, ready to implement this week. Key Takeaways: Culture Outruns CapitalPro Team > FamilyCandor Drives SpeedPay Top of MarketBet BoldlyContext Beats ControlTransparency = TrustTimestamps: (00:00) Intro – Why Netflix Scaled Faster by Removing Rules, Not Adding Them (04:30) Who Is Reed Hastings? – From Math Teacher to Global Disruptor (09:13) Book Snapshot – What Makes No Rules Rules a Real Operating System (11:35) Lesson 1: Culture Outruns Capital – How Netflix Survived 4 Disruptions, Blockbuster Didn’t Survive One (17:25) Lesson 2: Build a Pro Team, Not a Family – Talent Density Over Loyalty (22:48) Lesson 3: Radical Candor = Speed – The Feedback Model That Fuels Innovation (27:34) Lesson 4: Pay Like a Pirate – Why Netflix Pays Top of Market—No Games, Just Outcomes (32:20) Lesson 5: Bet Bold, Fail Proudly – The 4-Step Innovation Cycle That Keeps Netflix Ahead (39:12) Lesson 6: Lead with Context, Not Control – Scaling Leadership Without Becoming a Bottleneck (43:28) Lesson 7: Transparency Builds Velocity – How Truth-Telling Became Netflix’s Superpower (48:15) 7 Key Takeaways – The Culture Playbook Every Growth-Stage Founder Needs (50:15) Personal Reflection – What I Questioned, What I’ll Steal, What Gave Me Pause (52:00) Call to Action + What’s Next – Support the Show + Tease of the Next Episode Why Listen: Found this useful? Like, share, and follow. Every signal grows the show—and brings in more elite guests ready to share the truths behind high-growth success. Send us a text Support the show Join the Podcast Newsletter: Link

Most cancer drugs fail. Not because the science is wrong—because we’re solving the wrong problems. The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there’s no second chance. Behind the headlines of “precision medicine,” there’s a deeper story nobody’s telling. Until now. 🎯 Enter Rafael Rosengarten, the scientist-turned-founder who’s rewriting the rules of drug development. In this gripping conversation, we unpack how RNA, AI, and deep empathy could finally close the loop between biology, data, and the patient in the room. 🎧 Watch now to explore: 1️⃣ Why drug failure isn’t a tech problem—it’s a strategy problem 2️⃣ How “information companions” will guide every medicine to the right patient 3️⃣ What pharma keeps getting wrong about biomarkers—and how to fix it 4️⃣ The untold story behind turning down a chef’s job on a Mediterranean yacht 5️⃣ The real reason Genialis may one day go out of business (and why Rafael hopes it does) 👤 About Rafael Rosengarten Rafael is CEO and co-founder of Genialis, the RNA biomarker company reshaping precision oncology. From academic labs to Michelin-star kitchens, his journey is anything but linear—but his mission is clear: make medicine make sense. With partners across pharma, diagnostics, and AI, Genialis is creating a world where every patient gets the treatment they actually need. 💬 Quotes That Might Shift Your Thinking: (00:58:37) “Our AI biomarkers de-risk clinical trials, slashing costs and saving lives.” (01:54:46) “Every drug will have an information companion guiding it to the right patient.” (01:14:32) “AI should free humans for empathy and creativity, not replace them.” (00:14:13) “We now have the tools to treat every cancer as unique to each patient.” (01:31:38) “Stop selling technology; sell solutions to real problems.” 🧭 Timestamps to Explore: (00:03:52) Inside the World’s Largest Medical Center (00:10:30) How AI Is Rewiring Precision Medicine (00:13:51) Why Precision Medicine Is Scaling Now (00:17:34) Startups Must Solve Market Needs First (00:23:53) Culture First, Then Business: Startup Blueprint (00:27:57) Cancer Isn’t One Disease—It’s Thousands (00:31:44) Predicting Drug Success with AI Biology (00:36:40) Reimagining Biomarkers Using RNA and AI (00:47:45) Why Early Detection Still Saves Lives (00:57:30) Why Most Cancer Drugs Still Fail (00:58:37) AI Biomarkers That De-Risk Clinical Trials (01:09:42) Rethinking Dosage with Predictive Algorithms (01:13:33) Why Human Intuition Still Matters in Science (01:36:41) The Crystal Ball Question Pharma Can’t Ignore (01:50:19) The moment where time disappears—and the real future begins. (01:53:39) Every Drug Will Have an AI Companion 🔔 Let’s Rebuild Trust in Medicine—Together If this episode sparked a new thought—or just gave you pause—don’t let it end here. Subscribe. Share it with someone who still believes medicine can be both scientific and deeply human. Every action brings in minds like Rafael’s… and gets us one step closer to treatments that truly heal. 🎧 Watch now—and discover how medicine gets smarter, safer, and more personal. Send us a text Support the show Join the Podcast Newsletter: Link

Europe has the science. The talent. The breakthroughs. But when an idea feels too uncertain, our systems shut it down before it has a chance to breathe. And with every safe bet… we quietly lose the next cure, the next Car-T, the next AI that could change everything. 🚨 Risk-aversion, fragmentation, and bureaucracy are draining Europe’s innovation power—and nobody dares to name it out loud. But Fabrizio Conicella, VP of Open Innovation at Chiesi Group, isn’t holding back. 💡 In this deep, urgent conversation, Fabrizio shares how Europe can build the ecosystems we need to turn bold ideas into real-world impact—without compromising ethics, patients, or long-term value. 🎧 Watch now to explore: 1️⃣ Why uncertainty, not risk, is the true frontier of innovation 2️⃣ The hidden reasons startups leave Europe—and how to keep them 3️⃣ How Chiesi’s “The Impulse” model flips corporate R&D on its head 4️⃣ What every policymaker, CEO, and scientist must change before it’s too late 5️⃣ A bold new playbook for turning visionary science into trusted medicine 👤 About Fabrizio Conicella: As one of Europe’s leading voices in health innovation, Fabrizio is pioneering how pharma collaborates across startups, data, and ethics. His mission: create environments where the best ideas don’t get shut down—they get built. 💬 Quotes That Might Just Change Your Thinking: (01:58:01) "Be bold enough to dream, but pragmatic enough to make it real." (01:07:22) "Science is essential, but turning it into a product requires a different kind of wisdom." (01:04:35) "Visionary entrepreneurs see the future and change the game." (00:16:51) "Innovation today is no longer a race for ownership, but a journey of collaboration." (00:47:55) "If the idea is truly bold, no pharma company can replicate it without you." ⏱️ Timestamps: (03:00) Europe’s Innovation Crisis: A Wake-Up Call (08:19) Chiesi’s Bold B Corp Strategy (16:26) Building Healthcare Innovation Ecosystems (22:09) Predictive Medicine and Patient Data (29:49) Pharma vs. Startup Ecosystems Today (34:38) Why R&D Must Go External (35:06) The End of Buy-and-Wait Pharma (41:42) Ethics First: Pharma’s New Mandate (44:06) Respecting Founders, Not Just IP (47:23) Debunking the 'Pharma Steals Ideas' Myth (54:10) Why Pharma Moves Slowly—but Must Adapt (59:25) Market Acumen: Startups’ Missing Ingredient (01:04:35) What Makes a Visionary Entrepreneur (01:29:22) Embracing Failure to Spark Innovation (01:46:01) Europe’s Risk Culture is Holding Us Back 🔔 Help Us Grow the Future of Thoughtful Innovation If this conversation sparked something in you—an insight, a question, a sense of urgency—help us keep it alive. Subscribe. Leave a comment. Share it with someone who still believes bold ideas deserve a fighting chance. Every action brings in deeper minds, bigger questions, and the kind of leadership our systems so desperately need. 🎧 Watch now—and join the movement to rebuild Europe’s innovation edge. Send us a text Support the show Join the Podcast Newsletter: Link

What if the only way to save the planet... is to cool it? Not figuratively—literally. Because the heatwaves, floods, and fires you’ve seen so far? They’re just the beginning. 🌍 Emissions keep rising. Global cooperation is slowing. And the window to act is closing fast. Now, world leaders are quietly weighing a radical idea: Should we artificially cool Earth before it’s too late? 💥 In this explosive episode, we dive into the most controversial climate strategy on the table today: solar radiation modification. But who decides how much cooling is “enough”? What happens if we act too late—or worse, too soon? 📌 In this episode, Janos Pasztor—former UN Assistant Secretary-General for Climate Change and climate advisor to Ban Ki-moon—breaks his silence on the plans world leaders are only now beginning to confront. 🎧 Watch now to uncover: 1️⃣ Why geoengineering may soon become a global necessity—not a fringe idea. 2️⃣ What governments aren’t telling you about unilateral climate interventions. 3️⃣ The ethical, political, and scientific minefield behind planetary cooling. 4️⃣ Why some scientists say this tech could save millions—and others call it madness. 5️⃣ What it will take to govern Earth’s thermostat before someone does it alone. 👤 About Janos Pasztor: With nearly 50 years of experience in climate policy, diplomacy, and governance, Pasztor has shaped global climate strategy from inside the UN and beyond. From the 1992 Earth Summit to the corridors of the UN Security Council, he’s been advising heads of state on how to confront the world’s most complex crisis—and now, he’s sharing what’s coming next. 💡 Quotes to Challenge Your Thinking: (00:08:41) “We must ask: is it time to start cooling parts of the planet?” (01:21:07) “Stratospheric aerosol injection could cool the planet—yet we barely understand its consequences.” (01:11:03) “The real question is whether capitalism can evolve beyond its dependence on resource extraction.” (02:24:41) “Three degrees of warming is cuckoo land—it’s beyond what humanity can realistically adapt to.” (02:47:03) “Climate policy isn't just climate—it’s about everything we do as a society.” ⏱️ Timestamps: (00:04:12) Urgent Climate Crisis: Rising Emissions Explained (00:10:15) Inconvenient Truth 2.0: What We Missed (00:18:32) China’s Green Tech Revolution Unpacked (00:26:20) Can Climate Forums Deliver Real Action? (00:32:50) Designing Just, Achievable Climate Goals Globally (00:40:06) How Growth Triggers Today’s Polycrisis (00:45:08) Rethinking Economies for Sustainable Living (00:53:00) Why We Need Mixed Energy Strategies (01:17:24) Geoengineering vs Terraforming: Climate Futures Debate (01:26:20) Who Funds Carbon Removal Technologies? (01:37:06) Why We May Need to Cool Earth (01:40:41) Warming Beyond 3°C: What’s at Risk (01:48:02) How Fossil Fuels Hide True Heat (02:08:00) The Hidden Risks of Cheap Climate Fixes (02:24:41) 3 Degrees Warming: Scientifically Unmanageable? 🔔 Help Us Grow If this conversation gave you insight, urgency, or a new perspective—help us keep it going. Subscribe. Leave a comment. Share it with someone who cares. Every single action helps us invite world-class thinkers, spark deeper debates, and bring you the conversations that actually matter. 🎧 Watch now—and be part of the climate conversation no one dares to start. Send us a text Support the show Join the Podcast Newsletter: Link

What if your business ran like a well-designed machine—one that could evolve, self-correct, and outperform your competition over decades? In this episode, I unpack Principles by Ray Dalio, the billionaire investor and founder of Bridgewater Associates, the world’s largest hedge fund. It’s not a traditional business book—it’s a blueprint for decision-making, culture design, and long-term scaling, rooted in clarity, transparency, and radical self-honesty. This episode is built for venture capitalists, executives, and operators leading at scale—those who are no longer improvising but building enduring systems. You’ll hear the 7 most actionable principles Dalio used to scale Bridgewater, reimagined for anyone building the future—from biotech to AI, from global funds to market-leading enterprises. We cover how to engineer feedback cultures, design for evolution, and drive decisions that compound over time. And we tackle the big question: Can you be both a high-performance machine and a human-centered leader? Key Takeaways: Timestamps: (00:00) Intro: The Principles (02:15) Why This Book Matters If You’re Building or Investing in the Future (04:14) Who Is Ray Dalio? (06:21) The Snapshot: What Principles Is Really About (10:05) Build Your Company Like a Machine, Not a Hero’s Journey (15:29) Get the People Right (20:40) Radical Truth & Transparency Are Force Multipliers (26:08) Build an Idea Meritocracy (32:26) Shapers Win—They Dream Big, Think Clear, Execute Ruthlessly (37:37) Diagnose Root Causes, Not Symptoms (44:02) Be Radically Open-Minded (50:12) Key Takeaways & Personal Reflection Why Listen: If these ideas resonate, I strongly recommend reading Principles in full. Or better yet—share this episode with someone you think is ready to level up how they lead and build. Send us a text Support the show Join the Podcast Newsletter: Link

What does it take to turn extreme adversity into extraordinary leadership? Suzanne Heywood’s life reads like a novel—shipwrecked at seven, isolated at sea for a decade, forging her father’s signature to survive, and ultimately earning a place at Oxford through sheer determination. Today, she’s a top executive and investor, steering multi-billion-dollar companies with resilience, clarity, and innovation. In this episode, Suzanne shares the defining moments that shaped her, the mindset that helped her thrive in crisis, and the leadership lessons she applies in business today. Whether you’re an investor, entrepreneur, or leader, this conversation will leave you inspired and armed with valuable insights: How to stay calm under extreme pressure and make clear decisions.Why resilience isn’t about being tough—but about perspective.How diversity fuels innovation and why biases hold companies back.The ‘Critical Friend’ approach to leadership and board dynamics.At the heart of it all, Suzanne’s journey is a testament to perseverance and purpose. As she says: "You’ll learn things from adversity that people with an easier life never will." Timestamps & Topics 📌 (01:00) Overcoming Extreme Adversity – A childhood lost at sea, a future built from nothing. 📌 (03:43) Knowing Which Mountains Are Worth Climbing – How to distinguish real challenges from distractions. 📌 (06:05) Resilience Under Pressure – From shipwreck to boardroom calm. 📌 (07:51) The Dangers of Bias in Innovation – Why lack of diversity kills progress. 📌 (09:39) Creating Sustainable Innovation – What great leaders prioritize for long-term success. 📌 (13:48) The ‘Critical Friend’ in Leadership – Balancing support with hard truths. 📌 (16:43) Metallica Meets Electric Trucks – A masterclass in creative partnerships. 📌 (18:29) Education as the Ultimate Investment – How learning transformed her life. Powerful Quotes 💡 (03:43) "I picked kiwifruit… earned enough for a one-way ticket—Oxford changed my life." 💡 (06:58) "Nobody's life is in danger—we will get this sorted out." 💡 (20:39) "You’ll learn things from adversity that people with an easier life never will." This episode is more than an inspiring story—it’s a blueprint for navigating uncertainty, making tough decisions, and leading with conviction. 👉 Listen now, take notes, and if this sparks something in you, share it with someone who needs to hear it! Send us a text Support the show Join the Podcast Newsletter: Link

ATMPs, gene therapies, and cancer breakthroughs are here—but outdated regulations, high costs, and logistical bottlenecks are blocking access. What needs to change for hospitals to deliver these cures to patients who need them most? 💡 Here’s the harsh reality: So what’s the solution? And who’s taking action? 📌 In this episode, Kristina Levan—ATMP innovation leader and biotech strategist—breaks down the challenges and opportunities shaping the future of advanced therapies. 🎧 Watch now to learn: 1️⃣ How gene therapy is curing blindness—and why it almost didn’t happen. 2️⃣ The biggest bottleneck preventing hospitals from offering life-saving treatments. 3️⃣ How AI and automation could unlock personalized medicine for everyone. 4️⃣ The real reason ATMPs are so expensive—and what must change. 5️⃣ Why healthcare leaders, policymakers, and investors must rethink how we manufacture cures. 👤 About Kristina Levan: Kristina Levan has spent years at the cutting edge of cancer research, clinical trials, and ATMP development. She’s helped shape Sweden’s national ATMP strategy, connecting industry, healthcare, and academia to push these breakthroughs forward. Now, she’s tackling the next big challenge—getting these treatments to patients faster. 💡 Quotes to Challenge Your Thinking: (00:12:05) "ATMPs don’t just treat symptoms—they have the power to cure diseases." (00:23:36) "Gene therapy is giving children a future—restoring sight and transforming their lives forever." (01:27:52) "Imagine a future where hospitals create customized gene therapies on-site for every patient." (01:43:13) "ATMPs could transform lives by treating the untreatable." (01:45:42) "If we can cure early, we don’t just save lives—we reshape them." Timestamps: (00:05:32) How ATMPs Will Reshape Global Healthcare (00:13:54) CAR-T Therapy: The Next Cancer Treatment Revolution (00:23:36) Gene Therapy Restores Sight—The Future of Medicine? (00:28:33) AI-Powered Therapies: Can Hospitals Manufacture Cures? (00:37:55) Why Cutting-Edge ATMPs Struggle to Reach Patients (00:53:36) Personalized Medicine & Real-Time Health Monitoring (01:09:02) From Research to Reality: Scaling ATMP Treatments (01:12:54) The True Cost of ATMPs—Can We Afford Innovation? (01:27:15) Cell Therapy Manufacturing: The Next Big Disruption (01:33:03) AI & Automation in Healthcare: What’s Next? 🔔 Help Us Grow If this episode gave you insight, inspiration, or a new perspective—here’s how you can help: 📢 Hit SUBSCRIBE, like, and leave a comment. It’s a small action, but it has a huge ripple effect. Every engagement helps us bring in bigger guests, deeper insights, and more industry-changing conversations. Right now, we’re in the global top 10%—let’s push for the top 1% together. 🎧 Watch now and be part of the conversation shaping the future of medicine. 🚀 Send us a text Support the show Join the Podcast Newsletter: Link

In 2021, biotech IPOs were soaring. Valuations hit record highs. Investors were throwing money at anything that moved. Then… the market crashed. Funding dried up. Growth stalled. Biotech founders and investors were left scrambling. So what really happened? And more importantly—how do you navigate what’s next? 📌 In this episode, Christopher Uhde—Senior Pharma & Biotech Equity Analyst at SEB—breaks down the brutal realities of biotech IPOs, investor sentiment, and the high-stakes game of survival in a post-boom world. 🎧 Watch now to learn: 1️⃣ Why valuations aren’t about science—but about demand. 2️⃣ The biggest mistake biotech founders make after going public. 3️⃣ How to raise capital before you actually need it. 4️⃣ The European biotech advantage—and how to leverage it. 5️⃣ How to attract the right investors and avoid the wrong ones. 👤 About Christopher Uhde: Christopher Uhde is a Senior Pharma & Biotech Equity Analyst at SEB, one of Europe’s leading financial institutions. With a PhD in neurodevelopmental systems biology and postdoctoral research in drug discovery, he’s spent years studying the biotech market—from billion-dollar giants to early-stage startups—analyzing their success, failures, and what separates winners from the rest. 💡 Quotes to Challenge Your Thinking: 📌 (00:16:29) "Valuation isn’t about science; it’s about demand and the right investors." 📌 (00:49:17) "The power of the right team in biotech can’t be overstated." 📌 (01:13:08) "European startups struggle not from lack of innovation, but from a lack of ownership mindset." 📌 (01:38:39) "The long-term equity story isn’t just about share price—it’s about trust and vision." 📌 (01:50:44) "Biotech isn’t just about breakthrough science—it’s about strategy, trust, and long-term vision." ⏰ Timestamps: (00:09:48) IPO Market Realities and Investor Sentiment (00:17:59) Why European biotech should think beyond US listings (00:25:15) The hidden challenges of taking a company public (00:28:45) Preparing for IPO Compliance (00:37:11) Public company leadership demands strategic communication (00:49:17) The power of the right team in biotech (00:52:48) Planning for success in biotech acquisitions (01:13:08) Incentivizing Innovation in Europe (01:23:33) Nordic IPO culture shaping biotech success (01:36:16) Realistic Communication in Biotech (01:50:44) Europe’s Biotech Global Edge 🔔 Help Us Grow If this episode gave you insight, inspiration, or a new perspective—here’s how you can help: 📢 Hit SUBSCRIBE, like, and leave a comment. It’s a small action, but it makes a huge difference. Every engagement helps us bring in more top-tier guests, deeper insights, and the conversations that keep you ahead. Right now, we’re in the global top 10%—let’s push for the top 1% together. 🎧 Watch now and make sure your biotech strategy is built to last. 🚀 Send us a text Support the show Join the Podcast Newsletter: Link

🚀 Most investors chase consensus. The best ones? They bet against it. If everyone agrees on an investment, it’s probably not bold enough. That’s why the greatest venture capitalists don’t just follow trends—they seek out the hidden outliers that redefine industries. But how do they spot the next Amazon, Google, or Tesla before anyone else? And why do so many leaders play it safe and miss out? 📌 In this episode, Alex Dang—former Amazon and McKinsey leader—breaks down how elite investors think, how to cultivate the venture mindset, and why risk isn’t the enemy—short-term thinking is. 🎧 Watch now to learn how to think like the world’s top investors. 🎙️ What’s in the Episode: 1️⃣ Conviction Over Consensus – Why the best decisions often go against the crowd. 2️⃣ The VC Playbook – How top investors filter out noise and double down on outliers. 3️⃣ Risk vs. Regret – The hidden cost of playing it safe. 4️⃣ The ‘Day One’ Mentality – How Amazon avoids stagnation and bureaucracy. 5️⃣ From Poker to Investing – The mindset shift that separates amateurs from professionals. 👤 About Alex Dang: Alex Dang has lived the venture mindset firsthand—at Amazon, where he built new businesses; at AWS, where he launched cutting-edge AI solutions; and at McKinsey, where he helped Fortune 500 leaders scale transformative innovations. A Stanford GSB graduate, he’s spent nearly two decades guiding decision-makers through high-risk, high-reward environments. 💡 Quotes to Challenge Your Thinking: 📌 (01:21:31) "Conviction beats consensus. If everyone agrees, the idea isn’t bold enough." 📌 (01:49:18) "VCs don’t fear losing money. They fear missing the next Google." 📌 (00:31:08) "Home runs matter, strikeouts do not in the venture capital game." 📌 (00:58:46) "In business, like poker, fold early or double down—there’s no in-between." 📌 (00:47:00) "The moment you abandon a Day One mentality, bureaucracy wins." ⏰ Timestamps: (00:04:58) AI's Next Big Disruption (00:20:08) Predictability vs. Innovation in Business (00:30:45) Venture Capital’s Risk Culture Explained (00:38:00) How Amazon Built a Venture Mindset (00:46:34) Day One vs. Day Two Thinking (00:53:22) Writing for High-Stakes Decision Makers (00:57:51) Poker Mindset in Venture Investing (01:11:07) Why Failure Leads to Billion-Dollar Wins (01:21:31) Conviction vs. Consensus in Investing (01:26:46) Avoiding the Crowd, Finding Outliers (01:32:47) Playing the Long Game in Venture (01:54:59) Optimism in Innovation’s Unpredictable Future 🔔 Help Us Grow If this episode challenged your thinking, hit follow, like, and share. The bigger the show gets, the bigger the guests we can bring you—so you get even more game-changing insights. 🎧 Watch now and start making billion-dollar bets like the world’s best investors. 🚀 Send us a text Support the show Join the Podcast Newsletter: Link

What if your greatest asset in business was how you think under pressure? In this episode, I dive into The Venture Mindset by Alex Dang and Ilya Strebulaev, unpacking seven transformative lessons drawn from the world of venture capital and deep-tech entrepreneurship. These principles aren’t just for investors—they’re a roadmap for anyone navigating uncertainty, from startup founders to corporate innovators. Alex Dang, a veteran innovator, and Ilya Strebulaev, a leading academic in venture capital, combine decades of hands-on experience and rigorous research. Together, they reveal how to embrace risk, think strategically, and build ventures that thrive in chaotic environments. As an entrepreneur and investor, I’ve found these lessons invaluable. This episode explores how to prepare your mind for contrarian thinking, align incentives for growth, and make bold decisions when it matters most. Whether you’re building groundbreaking technology or adapting to a disruptive market, these insights will reshape how you approach challenges. Key Takeaways: This episode covers seven critical lessons, including: 1️⃣ Home Runs Matter, Strikeouts Don’t: Embrace failure as a stepping stone to transformative success. 2️⃣ Prepare Your Mind for Contrarian Thinking: Spot opportunities others miss and thrive in uncertainty. 3️⃣ Bet on the Jockey, Not Just the Horse: Prioritize resilient founders over flashy ideas. 4️⃣ Double Down or Quit: Make disciplined decisions to invest or cut losses. 5️⃣ Get Outside the Four Walls: Source ideas from diverse networks and unexpected places. 6️⃣ Make the Pie Bigger: Align incentives to foster collaboration and shared success. 7️⃣ Great Things Take Time: Cultivate patience and a long-term vision to achieve exponential impact. While this episode highlights actionable takeaways, The Venture Mindset is packed with even more insights and strategies for anyone looking to excel in unpredictable environments. Timestamps: (00:00) - Introduction: Why This Episode Matters (01:20) - The Book’s Relevance for Entrepreneurs and Innovators (02:02) - Author Spotlight: Alex Dang and Ilya Strebulaev (04:15) - Book Overview: A Roadmap for Thriving in Uncertainty (06:56) - Key Takeaway 1: Home Runs Matter, Strikeouts Don’t (12:43) - Key Takeaway 2: Prepare Your Mind for Contrarian Thinking (19:07) - Key Takeaway 3: Bet on the Jockey, Not Just the Horse (24:00) - Key Takeaway 4: Double Down or Quit (29:22) - Key Takeaway 5: Get Outside the Four Walls (34:00) - Key Takeaway 6: Make the Pie Bigger (38:53) - Key Takeaway 7: Great Things Take Time (43:55) - Closing Reflections and Final Insights Why Listen: Embrace Bold ThinkingMaster Decision-MakingDrive Innovation and GrowthPractical ApplicationIf these lessons resonate, I encourage you to explore The Venture Mindset in full. It’s more than a book—it’s your guide to navigating uncharted waters and building a futur Send us a text Support the show Join the Podcast Newsletter: Link